[纳武利尤单抗](https://zhida.zhihu.com/search?content_id=239239237&content_type=Article&match_order=1&q=%E7%BA%B3%E6%AD%A6%E5%88%A9%E5%B0%A4%E5%8D%95%E6%8A%97&zd_token=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpc3MiOiJ6aGlkYV9zZXJ2ZXIiLCJleHAiOjE3NjY4MDY5MTIsInEiOiLnurPmrabliKnlsKTljZXmipciLCJ6aGlkYV9zb3VyY2UiOiJlbnRpdHkiLCJjb250ZW50X2lkIjoyMzkyMzkyMzcsImNvbnRlbnRfdHlwZSI6IkFydGljbGUiLCJtYXRjaF9vcmRlciI6MSwiemRfdG9rZW4iOm51bGx9.5rChEXriom9JWwjRD7UCkf4PGGBK4HQwucbB1jxsrsY&zhida_source=entity)是首个获得临床批准的免疫疗法，也称为O-类药物。PD-1/PD-L1小分子抑制剂Opdivo的问世彻底改变了癌症治疗的方式。